Daniel F Hayes
#98,759
Most Influential Person Now
Researcher
Daniel F Hayes's AcademicInfluence.com Rankings
Daniel F Hayesengineering Degrees
Engineering
#2520
World Rank
#3452
Historical Rank
Electrical Engineering
#461
World Rank
#514
Historical Rank
Daniel F Hayescomputer-science Degrees
Computer Science
#3481
World Rank
#3653
Historical Rank
Data Science
#30
World Rank
#30
Historical Rank
Computational Linguistics
#184
World Rank
#188
Historical Rank
Machine Learning
#419
World Rank
#425
Historical Rank
Download Badge
Engineering Computer Science
Daniel F Hayes's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Daniel F Hayes Influential?
(Suggest an Edit or Addition)Daniel F Hayes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Circulating tumor cells, disease progression, and survival in metastatic breast cancer. (2004) (4105)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells (2003) (1605)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
- ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. (2006) (1441)
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007) (1333)
- Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) (1284)
- Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer (2018) (1273)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Revision of the American Joint Committee on Cancer staging system for breast cancer. (2002) (1236)
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. (2009) (1169)
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. (1998) (1107)
- Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. (2000) (1104)
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. (2015) (1097)
- Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. (2005) (1069)
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. (2007) (991)
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival (2006) (969)
- Use of archived specimens in evaluation of prognostic and predictive biomarkers. (2009) (954)
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. (2005) (932)
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer (2013) (915)
- 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. (2001) (886)
- 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years (2017) (840)
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. (2003) (837)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
- Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. (1996) (760)
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer (2006) (751)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016) (656)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. (2008) (603)
- Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. (1984) (600)
- Integrative Clinical Genomics of Metastatic Cancer (2017) (574)
- Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. (1994) (559)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. (2014) (508)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. (1994) (482)
- An international Ki67 reproducibility study. (2013) (475)
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment (2006) (468)
- The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. (1996) (437)
- HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
- Sensitive capture of circulating tumour cells by functionalised graphene oxide nanosheets (2013) (430)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) (423)
- Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. (2003) (398)
- Combination anastrozole and fulvestrant in metastatic breast cancer. (2012) (367)
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018) (367)
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018) (355)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. (2001) (318)
- Point-of-care biosensor systems for cancer diagnostics/prognostics. (2006) (318)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (313)
- Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. (1988) (312)
- Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. (1986) (311)
- Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. (2010) (297)
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer (2013) (297)
- American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (292)
- Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. (2003) (291)
- Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. (2012) (290)
- Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board (2006) (281)
- Cancer biomarkers (2012) (280)
- Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. (2001) (272)
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2015) (271)
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. (2019) (269)
- Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. (2013) (266)
- Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. (1998) (265)
- Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. (1997) (265)
- Review of Preoperative Magnetic Resonance Imaging (MRI) in Breast Cancer: Should MRI Be Performed on All Women with Newly Diagnosed, Early Stage Breast Cancer? (2009) (260)
- CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. (2012) (256)
- NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. (2011) (248)
- The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response (2007) (242)
- A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. (2000) (240)
- Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials (2012) (239)
- HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. (2012) (234)
- American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. (2010) (224)
- Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. (1985) (220)
- Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis (2001) (219)
- Dose-response in the treatment of breast cancer: a critical review. (1988) (218)
- Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. (1995) (218)
- Protocol for the examination of specimens from patients with invasive carcinoma of the breast. (2009) (217)
- Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. (2005) (214)
- An international study to increase concordance in Ki67 scoring (2015) (211)
- Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors (2013) (208)
- Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. (1993) (207)
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) (207)
- Breast cancer, version 3.2013: featured updates to the NCCN guidelines. (2015) (204)
- Human Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer (2008) (197)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors (2008) (196)
- Breast Cancer, Version 3.2013 (2013) (193)
- The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression (2016) (190)
- Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers (2013) (186)
- Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. (2011) (185)
- HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. (2000) (182)
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer (2002) (181)
- Breast cancer version 3.2014. (2014) (180)
- Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? (2004) (177)
- Publication of tumor marker research results: the necessity for complete and transparent reporting. (2012) (177)
- Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells (1996) (175)
- Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. (2009) (169)
- Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. (2002) (168)
- The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ (2007) (165)
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (2021) (164)
- Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. (1988) (163)
- Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. (2016) (163)
- Prechemotherapy alterations in brain function in women with breast cancer (2010) (162)
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. (2008) (161)
- Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients (2003) (159)
- Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. (2001) (156)
- Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation (2007) (153)
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients (2015) (152)
- Gene expression profiling of breast cancer: a new tumor marker. (2005) (152)
- Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 (2006) (152)
- Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. (2006) (145)
- 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. (1998) (145)
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist (2009) (144)
- Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. (2006) (144)
- Defining the benefits of neoadjuvant chemotherapy for breast cancer. (2012) (143)
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer (2017) (142)
- Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy (2005) (140)
- c-erbB-2 in breast cancer: development of a clinically useful marker. (2002) (137)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. (2020) (134)
- Invasive breast cancer. (2011) (133)
- Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. (2017) (130)
- Biospecimen Reporting for Improved Study Quality. (2011) (127)
- The measurement and therapeutic implications of circulating tumour cells in breast cancer (2005) (125)
- Validation of new cancer biomarkers: a position statement from the European group on tumor markers. (2015) (124)
- Biospecimen reporting for improved study quality (BRISQ) (2011) (124)
- Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. (1991) (124)
- Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. (2011) (122)
- Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. (2014) (122)
- A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. (2003) (121)
- Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. (2012) (120)
- New prognostic factors for breast cancer recurrence. (2001) (120)
- Phase II evaluation of thalidomide in patients with metastatic breast cancer. (2000) (119)
- Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. (1989) (118)
- Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration (2016) (116)
- Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. (1995) (115)
- Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. (2005) (114)
- Sentinel node biopsy prior to neoadjuvant chemotherapy. (2003) (114)
- Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer (2014) (113)
- Prognostic and predictive factors revisited. (2005) (113)
- Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients (2010) (112)
- Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. (2001) (111)
- Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
- Biomarker studies: a call for a comprehensive biomarker study registry (2011) (107)
- Biomarker validation and testing (2015) (106)
- Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer? (2008) (105)
- Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. (2002) (105)
- Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. (2012) (103)
- Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. (1992) (103)
- Biospecimen reporting for improved study quality (BRISQ). (2011) (103)
- International Web-based consultation on priorities for translational breast cancer research (2007) (98)
- Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. (2008) (95)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. (2016) (94)
- Comparison of HER-2 Overexpression in Primary Breast Cancer and Metastatic Sites and Its Effect on Biological Targeting Therapy of Metastatic Disease (2006) (94)
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age (2011) (89)
- Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid (2010) (89)
- Monitoring apoptosis and Bcl‐2 on circulating tumor cells in patients with metastatic breast cancer (2013) (87)
- Personalized medicine: risk prediction, targeted therapies and mobile health technology (2014) (86)
- Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy (2005) (86)
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. (2020) (85)
- Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer (2016) (83)
- Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer (1999) (83)
- Circulating tumor markers in breast cancer: Accepted utilities and novel prospects (2004) (80)
- p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. (2006) (80)
- Pretreatment worry and neurocognitive responses in women with breast cancer. (2014) (79)
- Association of angiogenesis in lymph node metastases with outcome of breast cancer. (2000) (79)
- Development and validation of sandwich ELISA microarrays with minimal assay interference. (2008) (79)
- Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants (2006) (79)
- Assessing the measure of a new drug: is survival the only thing that matters? (2008) (79)
- HER2 and Breast Cancer - A Phenomenal Success Story. (2019) (78)
- Breaking a Vicious Cycle (2013) (78)
- Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? (1998) (77)
- Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy (2014) (76)
- Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid (2011) (75)
- Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer (2019) (74)
- Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. (2018) (73)
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 (2015) (73)
- SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer (2016) (72)
- Treatment of metastatic breast cancer: present and future prospects. (1995) (72)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer (2018) (70)
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort (2009) (69)
- Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. (2009) (69)
- Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. (1991) (69)
- Healing flare in skeletal metastases from breast cancer. (1994) (68)
- Detection and quantitation of the human neu oncoprotein (1991) (68)
- Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221) (2011) (67)
- Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. (1997) (67)
- Activating ESR 1 mutations in hormone-resistant metastatic breast cancer (2013) (66)
- Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. (1986) (66)
- Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors (2021) (66)
- DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. (1990) (65)
- A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells (2019) (65)
- A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. (2004) (64)
- Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial (2018) (63)
- Follow-up of Patients with Early Breast Cancer (2007) (62)
- Pilot study of duloxetine for treatment of aromatase inhibitor‐associated musculoskeletal symptoms (2011) (62)
- Primary radiation therapy for locally advanced breast cancer (1987) (61)
- New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK (2006) (61)
- Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. (1986) (60)
- Invasive breast cancer. (2007) (60)
- New agents and new medical treatments for advanced breast cancer. (1987) (60)
- Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? (2009) (59)
- Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis (2017) (58)
- Targeting adjuvant chemotherapy: a good idea that needs to be proven! (2012) (58)
- Molecular testing in breast cancer. (2014) (58)
- Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313) (2017) (58)
- Circulating tumor markers in breast cancer. (1989) (58)
- Hot flushes (2002) (58)
- Heart of darkness: the downside of trastuzumab. (2006) (57)
- A Diet and Exercise Intervention during Chemotherapy for Breast Cancer. (2011) (57)
- Circulating tumour cells: insights into tumour heterogeneity (2013) (56)
- Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation (2014) (55)
- Bevacizumab treatment for solid tumors: boon or bust? (2011) (55)
- Prediction of postchemotherapy ovarian function using markers of ovarian reserve. (2014) (55)
- Modeling hot flushes and quality of life in breast cancer survivors (2011) (54)
- Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration (2019) (54)
- Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer† (2015) (52)
- Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. (2001) (52)
- Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer (2016) (51)
- Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. (2003) (51)
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. (2008) (51)
- Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. (1985) (50)
- Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. (1999) (50)
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer (2010) (49)
- Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial (2009) (49)
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer (2013) (49)
- Abstract S1-7: Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. (2010) (48)
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. (2009) (47)
- Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). (2016) (47)
- Promoting quality and evidence-based care in early-stage breast cancer follow-up. (2014) (47)
- Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. (2008) (46)
- Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210 (1999) (46)
- Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival (2020) (46)
- Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. (1999) (44)
- The role of c-erbB-2 as a predictive factor in breast cancer (2001) (44)
- Axillary Staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence (2008) (44)
- Clinical practice. Follow-up of patients with early breast cancer. (2007) (43)
- Angiogenesis as targeted breast cancer therapy. (2007) (43)
- Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance (2016) (42)
- Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. (2020) (42)
- Invasive Breast Carcinoma: Introduction and general features (2012) (42)
- Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial (2018) (42)
- Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer (2017) (41)
- A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography (2010) (41)
- Erratum: Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets (Nature Nanotechnology (2013) 8 (735-741)) (2013) (40)
- Do we need prognostic factors in nodal-negative breast cancer? Arbiter. (2000) (39)
- Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. (2001) (39)
- Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. (2010) (37)
- HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. (2006) (37)
- Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. (2020) (37)
- A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? (2008) (37)
- Circulating Tumor Cells. (2016) (37)
- Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study (2010) (36)
- Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study (2019) (36)
- Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer (2007) (36)
- A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. (2008) (36)
- Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. (2013) (36)
- Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. (2020) (36)
- Recent translational research: circulating tumor cells in breast cancer patients (2006) (34)
- Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator? (2015) (34)
- Predictors of recovery of ovarian function during aromatase inhibitor therapy. (2013) (34)
- Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. (2019) (34)
- Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy (2018) (34)
- Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. (2013) (34)
- Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial (2019) (34)
- Tumor markers for breast cancer. (1993) (34)
- The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer (2008) (33)
- Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). (2020) (33)
- Disseminated breast tumour cells: biological and clinical meaning (2018) (33)
- p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
- Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622 (2016) (31)
- Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. (2020) (30)
- Prognostic and predictive factors for breast cancer: translating technology to oncology. (2005) (30)
- Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. (1997) (30)
- Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects (2013) (30)
- SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. (2011) (30)
- Clinical predictors of long-term survival in HER2-positive metastatic breast cancer (2016) (29)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Germline genetic variants in ABCB1, ABCC1, and ALDH1A1 and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer (2013) (29)
- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer (2020) (29)
- Serum (circulating) tumor markers for breast cancer. (1996) (28)
- Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer. (2014) (28)
- Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer (2010) (28)
- Estrogenic Effects of Toremifene and Tamoxifen in Postmenopausal Breast Cancer Patients (2003) (28)
- Adjuvant therapy for all patients with breast cancer? (2001) (28)
- Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. (1990) (27)
- Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy (2018) (27)
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole (2012) (27)
- CAF in metastatic breast cancer: standard therapy or another effective regimen? (1987) (27)
- Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. (2009) (26)
- Indications for Prognostic Gene Expression Profiling in Early Breast Cancer (2015) (26)
- Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. (2002) (26)
- Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome (2017) (26)
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover (2015) (25)
- Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme (2006) (25)
- Angiogenesis and breast cancer. (1994) (25)
- Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer (2018) (25)
- Tamoxifen‐induced Radiation Recall Dermatitis (2004) (25)
- Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity. (2015) (24)
- Tamoxifen: Dr. Jekyll and Mr. Hyde? (2004) (24)
- Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients (1999) (24)
- Determination of clinical utility of tumor markers: a tumor marker utility grading system. (1998) (24)
- Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy (2009) (24)
- High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer. (1997) (24)
- Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. (1992) (24)
- OMICS-based personalized oncology: if it is worth doing, it is worth doing well! (2013) (23)
- ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. (2010) (23)
- Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. (2019) (23)
- Genotyping concordance in DNA extracted from formalin‐fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses (2015) (22)
- Markers of increased risk for failure of adjuvant therapies. (2003) (22)
- Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ (2006) (22)
- The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck (1986) (22)
- Circulating tumor cells. (2010) (21)
- Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer (2016) (21)
- Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection (2007) (21)
- Reply to E.A. Rakha et al. (2015) (21)
- Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. (2016) (21)
- Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307. (2015) (20)
- Tumor markers for breast cancer. Current utilities and future prospects. (1994) (20)
- Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci (2018) (20)
- ESR 1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients (2015) (20)
- Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment (2013) (19)
- Adjuvant systemic therapy for patients with node‐negative tumors (1990) (19)
- Elevated CA125 levels in patients with metastatic breast carcinoma. (1990) (19)
- Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer (2015) (19)
- A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia (2004) (19)
- Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. (1992) (19)
- Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. (2017) (19)
- Cooling off hot flashes. (2002) (19)
- Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells (2020) (18)
- Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? (2007) (18)
- Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: a prospective feasibility study in breast cancer patients. (1999) (18)
- Contribution of biomarkers to personalized medicine (2010) (17)
- Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (2012) (17)
- CYP2D6 genotype and tamoxifen response (2005) (17)
- Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer (2007) (17)
- Approach to menopausal symptoms in women with breast cancer (2002) (17)
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy (2015) (16)
- Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. (2008) (16)
- Personalized Medicine: Genomics Trials in Oncology. (2015) (16)
- Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC). (2016) (16)
- A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
- Do we need better prognostic factors in node-negative breast cancer? Pro, Contra and arbiter (2000) (16)
- Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer (2016) (15)
- Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. (2015) (15)
- S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226. (2011) (15)
- Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
- Biomarkers and oncology: the path forward to a learning health system. (2015) (15)
- Markers of endocrine sensitivity (2008) (14)
- BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received: Dawson S-J, Makretsov N, Blows FM, et al (Univ of Cambridge, UK; et al) Br J Cancer 103:668-675, 2010 (2011) (14)
- Clinical Applications of CA 15–3 (1992) (14)
- From genome to bedside: are we lost in translation? (2013) (14)
- Steady progress against HER2-positive breast cancer. (2011) (14)
- Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy (2009) (14)
- Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. (2019) (14)
- PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer (2021) (14)
- Breast Cancer (2023) (14)
- Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). (2011) (14)
- Implications for clinical management in patients with breast cancer. Long‐term effects of reconstruction surgery (1991) (13)
- Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC). (2014) (13)
- Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
- Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal? (2017) (13)
- Genome Medicine in Cancer: What's in a Name? (2015) (13)
- Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen (1988) (13)
- Atlas of breast cancer (1993) (13)
- Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. (2016) (13)
- SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery. (2014) (13)
- New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival (2006) (13)
- A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial (2018) (13)
- Abstract P3-11-16: S0800: Nab-paclitaxel, doxorubicin, cyclophosphamide, and pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) (2015) (12)
- CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. (2013) (12)
- Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations (2019) (12)
- Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC) (2005) (12)
- Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines (2015) (12)
- Reply to G. Sauter et al. (2009) (12)
- Innovations in American Society of Clinical Oncology Practice Guideline Development. (2016) (12)
- Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis (2005) (12)
- Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety. (2009) (12)
- A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity (2004) (12)
- Why Hasn't Genomic Testing Changed the Landscape in Clinical Oncology? (2012) (11)
- Further Progress for Patients with Breast Cancer. (2019) (11)
- TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. (2018) (11)
- Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy (2019) (11)
- Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. (2010) (11)
- Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation (2017) (10)
- Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. (2008) (10)
- Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein. (1990) (10)
- An academic health center cost analysis of screening mammography (2004) (10)
- A “breathalyser” for lung cancer? (1999) (10)
- 14 Sequencing of chemotherapy (CT) and radiotherapy (RT) following conservative surgery (CS) for patients with early-stage breast cancer: Results of a randomized trial (1995) (10)
- Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. (1988) (10)
- Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy (2020) (10)
- Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey™ device for CTC enrichment. (2021) (9)
- Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer (2017) (9)
- Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients (2021) (9)
- SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally advanced breast cancer (2016) (9)
- Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. (2022) (9)
- Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions (2019) (9)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. (2012) (9)
- Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. (2007) (9)
- OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007. (2011) (8)
- Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors (2017) (8)
- Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults. (2017) (8)
- Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. (1993) (8)
- Designing tumor marker studies: will the results provide clinically useful information. (2000) (8)
- Evidence-Based Management of Breast Cancer (2006) (8)
- Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem. (2004) (8)
- Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen. (1988) (8)
- The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 (2016) (7)
- Axillary lymphoscintigraphy for breast cancer: should we do it? Can we do it? (1990) (7)
- Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients (2017) (7)
- Tamoxifen therapy for patients with breast cancer (2013) (7)
- Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. (2016) (7)
- Clinical Applications of Circulating Tumor Cells in Breast Cancer. (2020) (7)
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
- ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. (2016) (7)
- Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
- Erratum: Promoting quality and evidence-based care in early-stage breast cancer follow-up (Journal of the National Cancer Institute (2014) 106:4 (dju034) DOI: 10.1093/jnci/dju034) (2014) (6)
- Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. (2019) (6)
- Factors influencing the use of extended adjuvant endocrine therapy (2019) (6)
- Ki67 as a Companion Diagnostic: Good or Bad News? (2022) (6)
- Breast-Cancer Recurrence after Stopping Endocrine Therapy. (2018) (6)
- Epithelial Cell Adhesion Molecule Expression in Canine Tumours. (2016) (6)
- Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? (2009) (6)
- Circulating tumor cells versus imaging : Predicting overall survival in metastatic breast cancer. Commentary (2006) (6)
- Evaluation of tumor markers: An evidence-based guide for determination of clinical utility (2006) (6)
- Considerations in using tumor markers: what the psycho‐oncologist needs to know (2001) (6)
- Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 (2009) (6)
- Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. (2019) (6)
- A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. (2009) (6)
- Circulating tumor cells - not serum tumor markers - predict survival in metastatic breast cancer (2005) (6)
- Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. (2017) (6)
- Is Breast Cancer a Curable Disease? (2016) (6)
- Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. (2004) (5)
- Bone Mineral Density (BMD) Changes at 1 Year in Postmenopausal Women Who Are Not Receiving Adjuvant Endocrine Therapy for Breast Cancer (BCA). (2009) (5)
- Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center. (2015) (5)
- Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm. (2013) (5)
- Refining breast cancer risk assessment with molecular markers: the next step? (1999) (5)
- Ductal carcinoma in situ of the breast: a new model. (1997) (5)
- Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. (2019) (5)
- Targeting Intrinsically-Resistant Breast Cancer Stem Cells with Gamma-Secretase Inhibitors. (2009) (5)
- Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. (2019) (5)
- CYP2D6 testing for breast cancer patients: is there more to the story? (2009) (5)
- Abstract P1-01-01: Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial (2017) (5)
- Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. (2014) (5)
- Abstract S3-02: Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy (2013) (5)
- Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. (2014) (5)
- Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy (2019) (5)
- Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion (2019) (5)
- Clinical trials: The silent minority—unpublished data on cancer care (2011) (4)
- Abstract 4464: Tumor-derived extracellular vesicles in blood of metastatic breast, colorectal, prostate, and non-small cell lung cancer patients associate with worse survival (2019) (4)
- A dormant sub-population expressing interleukin-1 receptor characterises anti-estrogen resistant ALDH+ breast cancer stem cells (2019) (4)
- Playing the old piano: another tune for endocrine therapy? (2003) (4)
- Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial. (2016) (4)
- Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (SEVI), a selective CYP17 lyase and AR inhibitor. (2017) (4)
- Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer: Turnbull AK, Arthur LM, Renshaw L, et al (Univ of Edinburgh Cancer Res UK Centre; et al) J Clin Oncol 33:2270-2278, 2015 (2016) (4)
- Book Review: Biomarkers in Breast Cancer. Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect (2006) (4)
- Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. (2020) (4)
- TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer. (2011) (4)
- Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer. (2020) (4)
- Prognostic value of cell cycle regulators p27 and cyclin E: Tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313 (2005) (4)
- Assessment of circulating tumor cells in breast cancer patients undergoing neoadjuvant chemotherapy. (2006) (4)
- Abstract P2-08-01: Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry (2016) (4)
- Abstract GS2-04: Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database (2020) (4)
- Improving Hormonal Therapy for Breast Cancer (1997) (4)
- The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife. (2004) (4)
- Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? (2006) (4)
- Clinical and Molecular Investigations of the DF3 Breast Cancer-Associated Antigen (1989) (4)
- P4-07-16: Development of Circulating Tumor Cell-Endocrine Therapy Index in Metastatic Breast Cancer Patients. (2011) (3)
- Cristofanilli M, Hayes DF, Budd GT et al.Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-30 (2005) (3)
- Inability to escalate vinorelbine dose intensity using a daily × 3 schedule with and without filgrastim in patients with metastatic breast cancer (1999) (3)
- Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. (2023) (3)
- Predictive and prognostic markers in cancer. (2011) (3)
- Reply to R. Bhargava et al and K. Lambein et al. (2014) (3)
- Psychosocial issues in breast reconstruction (1991) (3)
- Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim. (2006) (3)
- Response to Zhang and Yang. (2021) (3)
- Leukemia Group B Study Hormone-refractory Prostate Cancer Patients : A Cancer and Growth Factor Urine Levels as Predictors of Outcome in Vascular Endothelial Growth Factor and Basic Fibroblast (2001) (3)
- Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes (2012) (3)
- Erratum: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients (Journal of Clinical Pharmacology (2010) 50: 4 (450-458) DOI: 10.1177/0091270009359182) (2010) (3)
- Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms (2007) (3)
- Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer (2017) (3)
- Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study (2020) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective (2022) (3)
- Fine-needle aspiration and flow cytometry for evaluation of primary breast cancer. (1992) (3)
- Adult Preventive Health Care: Cancer Screening (2007) (3)
- Abstract S4-6: An international Ki67 reproducibility study (2012) (3)
- Pharmacogenomics and Endocrine Therapy in Breast Cancer. (2019) (3)
- Clinical Importance of Prognostic Factors (2008) (3)
- P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial. (2011) (3)
- Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity (2021) (3)
- Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator. (2009) (3)
- Quantitative measures of oestrogen receptor and ERBB2 expression. (2007) (2)
- Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker. (1991) (2)
- Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. (2009) (2)
- Breast Cancer? Should MRI Be Performed on All Women with Newly Diagnosed, Early Stage Review of Preoperative Magnetic Resonance Imaging (MRI) in Breast Cancer: (2009) (2)
- Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx). (2012) (2)
- Detection of Bcl-2 and apoptosis in circulating tumor cells during treatment of metastatic breast cancer (2008) (2)
- Adjuvant Systemic Therapy for Elderly Women with Breast Cancer (2006) (2)
- CirculatingTumor Cells versus ImagingPredicting Overall Survival in Metastatic Breast Cancer (2006) (2)
- Making a Difference in Cancer Care With You. (2017) (2)
- Abstract 4154: Multi-parameter molecular characterization of circulating tumor cells (CTC): Development of a CTC-endocrine therapy index (CTC-ETI) (2011) (2)
- Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). (2017) (2)
- Disease related indicators for a proper choice of adjuvant treatments. (2011) (2)
- Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial (2021) (2)
- Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection (2021) (2)
- Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models (2022) (2)
- The use of adjuvant therapy in patients treated with conservative surgery and radiotherapy. (1992) (2)
- Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations? (2017) (2)
- Tumour marker development: Towards validation of clinically useful markers (2007) (2)
- Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226 (2018) (2)
- Biomarkers in Breast Cancer (2006) (2)
- Book Review False Hope: Bone Marrow Transplantation for Breast Cancer By Richard A. Rettig, Peter D. Jacobson, Cynthia M. Farquhar, and Wade M. Aubry. 355 pp. New York, Oxford University Press, 2007. $49.95. 978-0-19-518776-2 (2007) (2)
- Abstract P4-02-01: Analytical validation of an automated digital scoring protocol for Ki67: International multicenter collaboration study (2019) (2)
- PD04-01: Predictors of Recovery of Ovarian Function during Aromatase Inhibitor (AI) Therapy. (2011) (2)
- Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients : A Cancer and Leukemia Group B Study 1 (2001) (2)
- Why Endocrine Therapy (2002) (2)
- Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. (1995) (2)
- 2–20 Gene-Expression Profiles to Predict Distant Metastasis of Lymph-Node-Negative Primary Breast Cancer (2006) (2)
- A Multicenter Randomized Clinical Trial Evaluating Interleukin-2 Activated Hematopoietic Stem Cell Transplantation and Post-transplant IL-2 for High Risk Breast Cancer Patients (2005) (2)
- Do all patients with breast cancer require systemic adjuvant therapy? (2011) (2)
- 10 – Breast Cancer (2010) (1)
- A Bad Tumor Marker Is as Bad as a Bad Drug: Applying Scientific Principles to Tumor Biomarker Research (2012) (1)
- Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI). (2014) (1)
- Association of Aromatase Inhibitor-Associated Musculoskeletal Symptoms with Ultrasonographic Changes at the Wrist. (2009) (1)
- Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival (2020) (1)
- Program Surveillance after Breast Cancer Treatment: Contra (2007) (1)
- Medical Oncologists and Risk Management in Breast Cancer (1994) (1)
- Abstract P6-08-50: Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC) (2015) (1)
- 203 A Clinician's Perspective on Metastatic Breast Cancer: Many Diseases – We Need to Understand the Biology (2012) (1)
- Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. (2016) (1)
- Cost-effective analyses in Breast Cancer Research and Treatment (2009) (1)
- Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors (2010) (1)
- Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data (2021) (1)
- PD04-08: Altered Neurocognitive Responses Prior to Adjuvant Therapy for Breast Cancer: A Functional MRI Analysis of the Impact of Worry and Fatigue. (2011) (1)
- PP-3-9 Acute toxicities of concurrent chemotherapy (CT) & reduced-dose radiotherapy (RT) for patients treated with breast-conserving surgery (1996) (1)
- Considerations in the development of circulating tumor cell technology for clinical use (2012) (1)
- Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313 (2019) (1)
- EPHA genetics for prediction of paclitaxel-induced peripheral neuropathy sensitivity. (2019) (1)
- Abstract 1776: Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple-negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313) (2017) (1)
- Abstract OT2-1-01: Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Ini (2015) (1)
- TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC). (2013) (1)
- Abstract P3-02-06: Correlation of BCL-2 and Apoptosis on Circulating Tumor Cells and Breast Cancer Tissue (2010) (1)
- Cyclin E as a prognostic factor: What is the question? (2009) (1)
- American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
- Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
- Abstract P1-08-11: Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy (2013) (1)
- Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer (2018) (1)
- Comment on: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Authors' reply (2004) (1)
- Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial (2021) (1)
- Abstract ES5-1: Predictive gene expression profiles in breast cancer, where are we? (2016) (1)
- Human epidermal growth factor receptor 2 testing recommendation. Authors' reply (2007) (1)
- Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner (2001) (1)
- Atlas of Breast Cancer, Second Edition (2002) (1)
- Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. (2009) (1)
- NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
- Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
- Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. (2015) (1)
- Abstract S6-3: Neurocognitive impact in adjuvant chemotherapy for breast cancer linked to fatigue: A Prospective functional MRI study (2012) (1)
- Abstract P6-15-03: Phase Ib Trial of the Gamma Secretase Inhibitor (GSI), MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer (2010) (1)
- Primary Chemotherapy of Resectable Breast Cancer (1995) (1)
- 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry (2015) (1)
- Abstract 5109: Integrated micro nanotechnology for the sensitive isolation of circulating tumor cells. (2013) (1)
- Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer (2020) (1)
- Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. (2022) (1)
- Abstract P6-13-05: Androgen receptor (AR): A novel target and mechanism for radiosensitization and treatment in triple-negative breast cancers (TNBC) (2016) (1)
- Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer (2023) (1)
- Radioiodination of DF3 antibody: Optimization using in vitro binding assays (1986) (1)
- Pretreatment Worry Predicts Neurocognitive Dysfunction in Women with Breast Cancer: (500822014-003) (2014) (0)
- Reply to J. Perlmutter et al and D. Yee et al (2012) (0)
- Author response for "Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer" (2020) (0)
- Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer (2017) (0)
- Revision o f t he A merican J oint C ommittee o n C ancer Staging S ystem f or B reast C ancer (2011) (0)
- Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy. (2012) (0)
- Current recommendations on breast cancer treatment. (1993) (0)
- Abstract P3-07-64: Association between gene variants in SULT1A1 and UGT1A4 and disease outcomes in patients enrolled in SWOG S0226 and treated with anastrozole alone or in combination with fulvestrant for metastatic breast cancer (2016) (0)
- Adjuvant chemotherapy for node-negative breast cancer (1990) (0)
- SA 3.4 - Clinical utility of “genomic” biomarkers in the adjuvant setting (2017) (0)
- Abstract A123: MGMT and MMR testing: NSCLC susceptibility to temozolomide (2009) (0)
- Book Review: Breast Cancer Research Protocols (2006) (0)
- Abstract P2-02-19: Somatic genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Update of Recommendat ions for the Use of Tumor Markers in Breast and Colorecta l Cancer : Cl in ica l Pract ice Guidel ines of the American Socie ty of Cl in ica l Oncology * (2001) (0)
- A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. (2021) (0)
- Pain sensitivity and aromatase inhibitor (AI)-associated arthralgias (AIAA). (2013) (0)
- National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer Reply (2015) (0)
- REMARK guidelines for tumour biomarker study reporting: a remarkable history (2022) (0)
- Abstract 4828: Circulating tumor cells (CTCs) isolated from patients with metastatic breast cancer utilizing a sensitive microfluidic graphene oxide (GO) nanosheet device express markers of cancer stem cells (2014) (0)
- Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing (2022) (0)
- Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer. (2022) (0)
- Erratum to: Editorial: Cost-effective analyses in Breast Cancer Research and Treatment (2011) (0)
- When Is Surrogate Marker Clinically Useful? Statistical and Clinical Significance May Not Be the Same (2000) (0)
- Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226) (2023) (0)
- Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Bone marrow micrometastases and circulating tumor cells (2014) (0)
- Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy. (2015) (0)
- Designing Tumor Marker Studies (2009) (0)
- Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer (2003) (0)
- Abstract PD6-4: Heterogeneity of expression of estrogen receptor by circulating tumor cells suggests diverse mechanisms of resistance to fulvestrant in metastatic breast cancer patients (2013) (0)
- Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC) (2016) (0)
- Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial (2021) (0)
- Preliminary Summary of the Consensus Discussion (2013) (0)
- Cancer Therapy : Clinical Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors (2013) (0)
- Abstract P4-12-13: High intratumoral and stromal S100A8 expression is prognostic of poor outcome in breast cancer (2017) (0)
- Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models (2022) (0)
- Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial (2021) (0)
- Is There a Role for Monitoring Circulating HER2 (2002) (0)
- Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration (2018) (0)
- Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial (2023) (0)
- Learning From Our Patients. (2017) (0)
- Abstract P2-11-11: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study (2023) (0)
- Sitting with grandma. (2013) (0)
- The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer: SECTION II: MOLECULAR AND CELLULAR MARKERS OF PROGNOSIS (2007) (0)
- • Complete Excision (Less Than Total Mastectomy, Including Specimens Designated Biopsy, Lumpectomy, Quadrantectomy, and Partial Mastectomy; With or Without Axillary Contents) • Mastectomy (Total, Modified Radical, Radical; With or Without Axillary Contents) (2009) (0)
- Abstract P2-09-26: Frequency and mechanisms of elevated somatic mutation burden in metastatic breast cancer and response to immune checkpoint blockade (2018) (0)
- Neratinib Ef fi cacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonampli fi ed Metastatic Breast Cancer (2017) (0)
- Comparison of CAI5-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer1 (2006) (0)
- CDK4/6 Inhibition and Radiation as a Treatment Strategy to Improve Local Disease Control in Breast Cancers With Poor Prognoses. (2021) (0)
- Abstract P1-09-05: Radiosensitization of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) cells using seviteronel (INO-464), a selective CYP17 lyase and AR inhibitor (2018) (0)
- Abstract 5489: A genome-wide association study identifies novel loci associated with taxane-related sensory neuropathy in breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221) (2015) (0)
- Abstract SY15-03: Coding and noncoding genome for blood biopsy (2019) (0)
- ‘Simoneʼs OncOpinion’ on the Death of NCCN Medical Director Christopher Desch, MD (1/25/07 issue) (2007) (0)
- Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis (2016) (0)
- Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer (2007) (0)
- Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer (2001) (0)
- Simoneʼs OncOpinion: ʼPersonalized Medicineʼ (5/10/08 issue) (2008) (0)
- A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells (2019) (0)
- Bevacizumab Treatment for Solid Tumors (2017) (0)
- Cancer screening. (2020) (0)
- The Integration of Radiotherapy and Chemotherapy in the Treatment of Early Breast Cancer (1989) (0)
- Development and Validation of a Method for Using Breast Core Needle Biopsies for Gene Expression Microarray Analyses 1 (2002) (0)
- Delivery of Personalized Medicine With Precision. (2017) (0)
- Abstract P4-02-04: Endocrine therapy treatment radiosensitizes estrogen receptor-positive breast cancers (2022) (0)
- Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes. (2009) (0)
- LETTERS: “ASCO Meetingʼs Inaugural ‘Trials in Progress’ Poster Session Gets Good Marks from Participants” (7/10/10 Issue) (2010) (0)
- How will the reporting recommendations for tumor marker prognostic studies affect clinical trials (2013) (0)
- Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer. (2018) (0)
- Progress in the Treatment of Breast Cancer. Reply. (2020) (0)
- Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients (2021) (0)
- Abstract 611: Assessment of tumor mutation burden and microsatellite instability by single-cell circulating tumor cell genomic profiling (2022) (0)
- Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
- Abstract 3413: Supplement use and chemotherapy-induced peripheral neuropathy in breast cancer patients treated on SWOG study S0221 (2016) (0)
- 47 Treatment-related cardiac toxicity from doxorubicin (DOX) and radiation therapy (RT) in patients treated with breast-conserving therapy (1996) (0)
- Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663 (2003) (0)
- Abstract 1700: Serial monitoring of single-cell circulating tumor cell genomics in metastatic lobular breast cancer to identify precision and immuno-oncology biomarkers with therapeutic implications (2022) (0)
- Circulating extracellular domain of HER2 can be correlated with clinical response to chemotherapy in locally advanced breast cancer (2001) (0)
- Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. (2022) (0)
- Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers (2011) (0)
- Comparison of CAI 5-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer 1 (2006) (0)
- Breast cancer screening and prevention. (1993) (0)
- Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference (2017) (0)
- 4–58 HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy (2007) (0)
- Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms (2022) (0)
- A comparison of two HER2 FISH methods to measure HER2 amplification and predict clinical outcome (2004) (0)
- Detection and Characterization of a High Molecular Weight Human Lung Carcinoma-associated Glycoprotein 1 (2006) (0)
- Variants in the BRCA1/Fanconi-Anemia Repair Pathway and Taxane-Induced Neuropathy in SWOG S0221. (2009) (0)
- EDITORIALS Adjuvant Therapy for All Patients With Breast Cancer (2001) (0)
- Dynamics of circulating tumor cells in mice bearing human breast cancer xenografts (2008) (0)
- Abstract P6-03-08: Androgen receptor (AR): A novel target for radiosensitization and treatment in triple-negative breast cancers (TNBC) (2015) (0)
- PG 1.02 Clinical utility of genetic signatures in selecting adjuvant treatment: risk stratification in early versus late recurrences (2015) (0)
- Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials (2012) (0)
- Association of in Lymph Node Metastases With Outcome of Breast Cancer (0)
- The explanation behind the observation (2007) (0)
- Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models (2022) (0)
- Is There aR ole for CirculatingTumor Cells in the Management of Breast Cancer (2008) (0)
- Abstract 444: Continuous, high throughput microfluidic device to monitor circulating tumor cells in cancer patients (2019) (0)
- ABSTRACTS IMP:05 ABSTRACTS Suppl 2-04 OK (2007) (0)
- Reply to F.-C. Bidard et al. (2015) (0)
- Book Review: DNA Repair Protocols. Mammalian Systems (2006) (0)
- 40P Development of Circulating Tumor Cell-Endocrine Therapy Index (CTC-ETI) in Metastatic Breast Cancer Patients (2012) (0)
- Invasive Breast CancerPractice Guidelines in Oncology (2011) (0)
- Abstract 4681: Effect of physician recommendation on multivitamin and antioxidant supplement use during chemotherapy in an adjuvant trial for breast cancer (SWOG S0221) (2011) (0)
- Vitamin D insufficiency and risk of paclitaxel-induced peripheral neuropathy. (2019) (0)
- New Technologies/New Markers/New Challenges (2006) (0)
- 3-48 Surrogate Markers and Survival in Women Receiving First-line Combination Anthracycline Chemotherapy for Advanced Breast Cancer (2006) (0)
- Abstract P2-12-02: Comorbidities and patient-reported cognitive function among women with stage I-II breast cancer randomized to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT) treated on theTrial Assigning IndividuaLized Options (2012) (0)
- Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer. (2021) (0)
- Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
- Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance (2023) (0)
- Commentary on “A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923” (2000) (0)
- Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates (2023) (0)
- Abstract 3151: Genetic profiling of circulating tumor cells (CTC) in metastatic breast cancer (MBC) patients (2016) (0)
- Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status (2023) (0)
- Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. (2020) (0)
- Abstract P5-12-05: CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (2016) (0)
- Abstract 2032: Germline genetic variants in GATA3 and breast cancer treatment outcomes in SWOG 8897 trial (2016) (0)
- Abstract 5839: Androgen receptor (AR): A novel target for radiosensitization in triple-negative breast cancers (TNBC) (2017) (0)
- Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. (2023) (0)
- Assessing Cognitive Function Prior to Chemotherapy for Breast Cancer Using Functional Magnetic Resonance Imaging (fMRI) (2011) (0)
- Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm (2022) (0)
- Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814 (2023) (0)
- Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019) (2013) (0)
- Development ofCirculatingTumorCell-Endocrine Therapy Index in Patients with Hormone Receptor – Positive Breast Cancer (2015) (0)
- Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists Initiative. (2021) (0)
- Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models (2022) (0)
- Biokinetics of a radioiodinated antibreast carcinoma monoclonal antibody and fragment in humans (1984) (0)
- Prognostic S ignificance o f R everse T ranscriptase P olymerase Chain R eaction f or P rostate-Specifi c A ntigen i n M etastatic Prostate C ancer: A N ested S tudy W ithin C ALGB 9 583 (2003) (0)
- Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx (2019) (0)
- Phase I I E valuation o f T halidomide i n P atients W ith Metastatic B reast C ancer (2000) (0)
- Front & Back Matter (2012) (0)
- Implementing circulating tumor cells in routine practice of breast cancer management: overview of the interventional trials (2013) (0)
- Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide. (2018) (0)
- Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
- CA15-3 and Related Antigens as Serum Markers for Monitoring Breast Cancer (1988) (0)
- Abstract S4-05: Interrogating the landscape of long noncoding RNAs in breast cancer to identify predictors of tamoxifen resistance (2016) (0)
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007) (2023) (0)
- Abstract P6-12-05: Targeting estrogen receptor mutations for treatment of endocrine therapy resistance in breast cancer (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Daniel F Hayes?
Daniel F Hayes is affiliated with the following schools:
- University of Utah
- Harvard University
- University of Nebraska Medical Center
- University of Amsterdam
- University of California, Berkeley
- MD Anderson Cancer Center
- University of Michigan
- University of Missouri
- University of Chicago
- Baylor College of Medicine
- Loyola University Chicago
- Duke University
- Yale University
- University of Arizona
- Inje University
- Stanford University
- Georgetown University
- Case Western Reserve University
